• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks

    Algernon: Repurposing Established Drugs to Create New Treatments

    Kevin Vanstone
    Jan. 17, 2020 11:30AM PST
    Pharmaceutical Investing
    CSE:AGN

    Algernon Pharmaceuticals Inc. (CSE:AGN; OTCQB:AGNPF; XFRA:AGW) has launched its campaign on the Investing News Network’s life science channel. 

    Algernon Pharmaceuticals Inc. (CSE:AGN; OTCQB:AGNPF; XFRA:AGW) has launched its campaign on the Investing News Network’s life science channel.

    Algernon is a clinical-stage pharmaceutical development company working to advance a portfolio of drugs targeting non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough.

    By leveraging existing drugs and applying them to new treatments, Algernon is attempting to shorten the lengthy drug development process, which can take five or six years before being approved for human testing. Using a drug repurposing strategy, Algernon intends to rapidly advance its drugs into a Phase 2 clinical study quickly and efficiently while reducing safety concerns.

    Algernon Pharmaceuticals’ company highlights include the following:

    • Planning its first phase II trial for idiopathic pulmonary fibrosis and chronic cough in Q2 2020.
    • Has a drug development program based on drug repurposing, which has a much lower risk of fail in human trials as a result of safety issues
    • Reduced time and cost to move compounds into a phase II trial due to advancing safe, approved well established small molecules
    • Company is advancing compounds that have matched or outperformed leading global treatments in animal studies
    • Multi-billion dollar global markets for disease treatments
    • Experienced management team and globally recognized medical advisory board
    • Capital-efficient business model

    Click here to connect with Algernon Pharmaceuticals (CSE:AGN; OTCQB:AGNPF; XFRA:AGW) and to request an investor presentation.

    cse:agnfrankfurt:agwalgernon pharmaceuticals incotcb:bthcf
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×